JP2010510495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510495A5 JP2010510495A5 JP2009537402A JP2009537402A JP2010510495A5 JP 2010510495 A5 JP2010510495 A5 JP 2010510495A5 JP 2009537402 A JP2009537402 A JP 2009537402A JP 2009537402 A JP2009537402 A JP 2009537402A JP 2010510495 A5 JP2010510495 A5 JP 2010510495A5
- Authority
- JP
- Japan
- Prior art keywords
- determining
- test mixture
- individual
- individual treatment
- treatment according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- 238000004760 accelerator mass spectrometry Methods 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 239000000700 radioactive tracer Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85973906P | 2006-11-17 | 2006-11-17 | |
| PCT/US2007/085033 WO2008064138A2 (en) | 2006-11-17 | 2007-11-17 | Personalized therapeutic treatment process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510495A JP2010510495A (ja) | 2010-04-02 |
| JP2010510495A5 true JP2010510495A5 (enExample) | 2011-01-13 |
Family
ID=39430529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537402A Pending JP2010510495A (ja) | 2006-11-17 | 2007-11-17 | 個別治療処置の方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2094861A4 (enExample) |
| JP (1) | JP2010510495A (enExample) |
| CN (1) | CN101702921A (enExample) |
| AU (1) | AU2007323782A1 (enExample) |
| BR (1) | BRPI0719314A2 (enExample) |
| CA (1) | CA2669864A1 (enExample) |
| WO (1) | WO2008064138A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0714040D0 (en) | 2007-07-19 | 2007-08-29 | Xceleron Ltd | Quantification of analytes |
| CN105467108A (zh) * | 2015-12-19 | 2016-04-06 | 开滦总医院 | 溶栓药物个体化应用剂量的体外测定试验方法 |
| US20200116657A1 (en) * | 2018-10-15 | 2020-04-16 | Olaris, Inc. | Nmr-metabolite-signature for identifying cancer patients resistant to cdk4/6 inhibitors, endocrine therapy and anti-her2 therapy |
| WO2021076058A1 (en) * | 2019-10-18 | 2021-04-22 | National University Of Singapore | Method for predicting a suitable therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4131544A (en) * | 1976-08-03 | 1978-12-26 | Nasik Elahi | Macroencapsulated sorbent element and process for using the same |
| US4880014A (en) * | 1987-08-14 | 1989-11-14 | Zarowitz Barbara J | Method for determining therapeutic drug dosage using bioelectrical resistance and reactance measurements |
| GB0304433D0 (en) * | 2003-02-27 | 2003-04-02 | Xceleron Ltd | Improvements relating to chemical libraries |
| EP1608966A2 (en) * | 2003-04-02 | 2005-12-28 | Celator Pharmaceuticals, Inc. | Methods to individualize combination therapy |
| DE602005027617D1 (de) * | 2004-09-20 | 2011-06-01 | Resonant Medical Inc | Radiotherapiebehandlungsüberwachung unter einsatz von ultraschall |
| NZ554574A (en) * | 2004-10-28 | 2009-08-28 | Albert Edward Litherland | Method and apparatus for separation of isobaric interferences |
| GB0504243D0 (en) * | 2005-03-02 | 2005-04-06 | Xceleron Ltd | Biological compositions labelled with radioisotope |
-
2007
- 2007-11-17 CN CN200780050039A patent/CN101702921A/zh active Pending
- 2007-11-17 BR BRPI0719314-9A patent/BRPI0719314A2/pt not_active IP Right Cessation
- 2007-11-17 CA CA002669864A patent/CA2669864A1/en not_active Abandoned
- 2007-11-17 EP EP07864570A patent/EP2094861A4/en not_active Withdrawn
- 2007-11-17 WO PCT/US2007/085033 patent/WO2008064138A2/en not_active Ceased
- 2007-11-17 AU AU2007323782A patent/AU2007323782A1/en not_active Abandoned
- 2007-11-17 JP JP2009537402A patent/JP2010510495A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walker et al. | Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice | |
| Kadriu et al. | Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments | |
| Haroon et al. | Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications | |
| Ghebremariam et al. | Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis | |
| Kirschneck et al. | Regular nicotine intake increased tooth movement velocity, osteoclastogenesis and orthodontically induced dental root resorptions in a rat model | |
| JP2013520681A5 (enExample) | ||
| Lim et al. | Development of metabolic and contractile alterations in development of cancer cachexia in female tumor-bearing mice | |
| JP2010540657A5 (enExample) | ||
| Askar et al. | Effects of exercise and ferulic acid on alpha synuclein and neuroprotective heat shock protein 70 in an experimental model of Parkinsonism disease | |
| JP2017519006A5 (enExample) | ||
| Sterzi et al. | Post-operative rehabilitation for surgically resected non-small cell lung cancer patients: serial pulmonary functional analysis. | |
| Spurney et al. | CINRG pilot trial of coenzyme Q10 in steroid‐treated duchenne muscular dystrophy | |
| Cooper-Knock et al. | Clinical and molecular aspects of motor neuron disease | |
| JP2010510495A5 (enExample) | ||
| Troutman et al. | Skeletal muscle complications in chronic kidney disease | |
| Zhang et al. | Involvement of kynurenine metabolism in bipolar disorder: an updated review | |
| CN105031212B (zh) | 一种治疗帕金森病的药物 | |
| Steiner et al. | Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. | |
| Xu et al. | Zhisou powder suppresses airway inflammation in LPS and CS-induced post-infectious cough model mice via TRPA1/TRPV1 channels | |
| Yang et al. | The dose limits of teeth protection for patients with nasopharyngeal carcinoma undergoing radiotherapy based on the early oral health-related quality of life | |
| CN102789550A (zh) | 一种利用跨物种相似性的元分析方法 | |
| Jordan et al. | Radiation‐induced oral mucositis hamster model using a linear accelerator enhances clinical relevance of preclinical studies for treatment strategy investigation | |
| Stefaniak et al. | In the search for the treatment of compensatory sweating | |
| Wei et al. | Altered gut microbial profiles in drug-treated rats with alcoholic heart disease | |
| Meduri et al. | Corticosteroids in ARDS: a counterpoint |